Biotech

EU biotech sector hits record €42.2bn in economic contribution as growth outpaces wider economy

Biotechnology products recorded average annual GVA growth of 4.7% in 2024

  • By IPP Bureau | November 18, 2026
Europe's biotechnology industry has delivered a record €42.2 billion in gross value added (GVA) in 2024, with growth significantly outpacing the wider EU economy, according to a new industry report.
 
The findings, published in the 2026 edition of Measuring the Economic Footprint of the Biotechnology Industry in the European Union, conducted by the WifOR Institute on behalf of EuropaBio, extend the analysis to cover 2008–2024 and track 117 biotechnology products across multiple sectors.
 
Biotechnology products recorded average annual GVA growth of 4.7% in 2024, comfortably ahead of the EU economy-wide average of 3.6%, highlighting the sector's expanding contribution to Europe's economic performance.
 
The industry's productivity advantage was equally striking. Biotechnology generated €188,400 in GVA per employee in 2024 – more than 2.5 times the EU average. Healthcare biotechnology was even more productive, generating €213,700 per employee.
 
The sector is also strengthening Europe's position in international markets. Extra-EU biotechnology exports reached €91.1 billion in 2024, reinforcing the industry's importance to the bloc's global trade performance.
 
Healthcare biotechnology exports remained substantially above 2020 levels despite retreating from their pandemic-period peak, while industrial biotechnology exports maintained a more consistent upward trajectory.
 
Employment figures further underline the sector's growing economic significance. Biotechnology employment growth in 2024 was almost four times the EU average, while industry investment in research and development remained robust at more than €6 billion annually.
 
The findings strengthen the case for biotechnology as a strategic driver of European growth, innovation and economic resilience, particularly as global competition and supply chain pressures intensify.
 
Claire Skentelbery, Director General of EuropaBio, commented: "Biotechnology continues as an economic powerhouse in the EU. It is essential that policymakers at EU and Member State levels place this technology at the heart of ambitions for growth and resilience. It has significance far beyond economics as the world reorders itself for supply chain power and regional strength."

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.